person · Reporting owner
Kassberg Thomas Richard
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 19, 2026 | May 21, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | CBO & EVP | March 01, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Passage BIO, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19 | Direct | 10,539 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Ultragenyx Pharmaceutical Inc.
Report date March 01, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 271,266 |
Reported balance
After 2025-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-01 · Grant · Acquired 18,443 · Balance 271,266 F1: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. |
| Common StockSEC Table I · non-derivative | Direct | 265,238 |
Reported balance
After 2025-03-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-03-03 · Sale · Disposed 6,028 · Balance 265,238 F2: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 264,730 |
Reported balance
After 2025-03-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-03-03 · Tax withholding · Disposed 508 · Balance 264,730 F4: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F5: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
F2: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F5: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Apr 17, 2019 22:05 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-025125 · doc4a.xml · derivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2029-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 22:05 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025125 · doc4a.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,306 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 191 shares acquired under the Company's 2014 Employee Stock Purchase Plan. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 346 | $73.73 | $25,510.58 |
DisclosureSEC source: 0001209191-18-035172 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,114 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 21, 2018 Filed May 22, 2018 15:46 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 381 | $64.79 | $24,684.99 |
DisclosureSEC source: 0001209191-18-032211 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,460 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 312 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2018. Read SEC document |
| April 19, 2018 Filed Apr 19, 2018 20:45 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-025591 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,529 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $48.43 | $0.00 |
DisclosureSEC source: 0001209191-18-016415 · doc4.xml · derivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 307 | $48.43 | $14,868.01 |
DisclosureSEC source: 0001209191-18-016415 · doc4.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,098 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016415 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,405 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 177 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2017. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 376 | $56.61 | $21,285.36 |
DisclosureSEC source: 0001209191-17-036971 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,228 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| May 21, 2017 Filed May 22, 2017 22:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 414 | $57.47 | $23,792.58 |
DisclosureSEC source: 0001209191-17-034484 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,604 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. F2 · balance_after: Includes 228 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 28, 2017. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 22:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $88.80 | $0.00 |
DisclosureSEC source: 0001209191-17-016073 · doc4.xml · derivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 22:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016073 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,790 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.